LONDON and NEW YORK , Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following upcoming events: 3rd Annual Chardan Genetic Medicines Conference in New York

LONDON and NEW YORK , Sept. 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company’s Phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings.

LONDON and NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 3,200,000 of its ordinary shares at a public offering price of $23.50 per

LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of $75 million of its ordinary shares.

LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended June 30, 2019 and provided an update on recent clinical progress.

• Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the treatment of achromatopsia LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a

AAV-RPE65 met the primary endpoint of safety and tolerability Statistically significant improvement demonstrated in vision-guided mobility and visual function in treated eyes compared to untreated eyes Dose selected for pivotal study; Company expects to meet with global regulatory authorities in

LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Directors. Ms. Seligman is an accomplished leader with extensive executive,

LONDON and NEW YORK , May 06, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the BAML Healthcare

LONDON and NEW YORK , April 25, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster on safety and efficacy of the Company’s gene therapy product candidate AAV-CNGA3 for the treatment of